NBIX vs. SNY: Neurocrine Biosciences vs. Sanofi Stock Comparison
How do Neurocrine Biosciences (NBIX) and Sanofi (SNY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Neurocrine Biosciences (NBIX) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NBIX is classified in Biotechnology while SNY is classified in Pharmaceuticals.
Neurocrine Biosciences (NBIX) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | NBIX | SNY |
|---|---|---|
| Name | Neurocrine Biosciences, Inc. | Sanofi ADR |
| Country/Region | United States | France |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 16.66 billion USD | 112.71 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | May 23, 1996 | July 1, 2002 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | NBIX | SNY |
|---|---|---|
| Total Return (1Y) | 9.40% | 2.73% |
| Total Return (3Y, Annualized) | 14.12% | 6.89% |
| Total Return (5Y, Annualized) | 12.61% | 3.16% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | NBIX | SNY |
|---|---|---|
| Volatility (1Y, Annualized) | 35.05% | 23.60% |
| Beta (5Y) | 0.29 | 0.28 |
| Max Drawdown (5Y) | -42.89% | -33.52% |
| Avg. Volume (3M) | 1.31M | 3.29M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | NBIX | SNY |
|---|---|---|
| Sharpe Ratio (1Y) | 0.15 | -0.07 |
| Sortino Ratio (1Y) | 0.22 | -0.10 |
Profitability
ROE (TTM)
Neurocrine Biosciences (NBIX) at 20.42% sits in the top ROE quartile, while Sanofi (SNY) at 5.72% is closer to the peer norm — stronger capital efficiency for NBIX.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.42%
- Max
- 109.18%
- NBIX
- 20.42%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.72%
- Max
- 109.18%
- Q3
- 6.23%
- SNY
- 5.72%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Neurocrine Biosciences (NBIX) at 18.98% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.98%
- NBIX
- 18.98%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.20%
- Max
- 18.05%
- SNY
- 8.20%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Neurocrine Biosciences (NBIX) at 31.98% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.98%
- Max
- 83.12%
- NBIX
- 31.98%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.89%
- Max
- 83.12%
- SNY
- 30.89%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | NBIX | SNY |
|---|---|---|
| ROE (TTM) | 20.42% | 5.72% |
| ROA (TTM) | 12.45% | 5.31% |
| Net Margin (TTM) | 18.98% | 8.20% |
| Operating Margin (TTM) | 31.98% | 30.89% |
| Gross Margin (TTM) | 64.67% | 73.68% |
Growth
Revenue Growth
Both Neurocrine Biosciences (NBIX) at 21.45% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Neurocrine Biosciences (NBIX) at 41.95% and Sanofi (SNY) at 39.43% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | NBIX | SNY |
|---|---|---|
| Revenue Growth (YoY) | 21.45% | 5.49% |
| Revenue Growth (3Y CAGR) | 24.32% | 4.82% |
| EPS Growth (YoY) | 41.95% | 39.43% |
| EPS Growth (3Y CAGR) | 44.12% | 6.02% |
Financial Strength
Current Ratio (MRQ)
Both Neurocrine Biosciences (NBIX) at 2.04 and Sanofi (SNY) at 1.12 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.04
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- NBIX
- 2.04
- Min
- 0.10
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.12
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- SNY
- 1.12
- Min
- 0.10
Debt / Equity (MRQ)
Both Neurocrine Biosciences (NBIX) at 0.12 and Sanofi (SNY) at 0.27 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.12
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NBIX
- 0.12
- Q1
- 0.02
- Min
- 0.00
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.27
- Max
- 1.42
- Q3
- 0.65
- SNY
- 0.27
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | NBIX | SNY |
|---|---|---|
| Current Ratio (MRQ) | 2.04 | 1.12 |
| Debt / Equity (MRQ) | 0.12 | 0.27 |
| Net Debt / EBITDA | -0.27 | 0.96 |
Dividends
Dividend Yield (TTM)
Neither Neurocrine Biosciences (NBIX) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NBIX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Neurocrine Biosciences (NBIX) pays no dividend (payout 0.00%).
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NBIX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
119.86%
- SNY
- 119.86%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | NBIX | SNY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 119.86% |
Valuation
P/E Ratio (TTM)
Both Neurocrine Biosciences (NBIX) at 24.43 and Sanofi (SNY) at 23.40 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.43
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- NBIX
- 24.43
- Q1
- 13.30
- Min
- 0.07
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.40
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- SNY
- 23.40
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Neurocrine Biosciences (NBIX) at 4.50 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- NBIX
- 4.50
- Q1
- 3.01
- Min
- 0.01
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.21
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- SNY
- 2.21
- Min
- 0.01
P/B Ratio (MRQ)
Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile against book while Neurocrine Biosciences (NBIX) at 4.30 is valued near its industry’s middle — SNY is cheaper on assets, though weigh it against ROE and asset quality.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.30
- Max
- 13.53
- Q3
- 6.54
- NBIX
- 4.30
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.38
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- SNY
- 1.38
- Min
- -5.59
Valuation Metrics
| Metric | NBIX | SNY |
|---|---|---|
| P/E Ratio (TTM) | 24.43 | 23.40 |
| P/S Ratio (TTM) | 4.50 | 2.21 |
| P/B Ratio (MRQ) | 4.30 | 1.38 |
| Free Cash Flow Yield (TTM) | 6.11% | 7.17% |